Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | BTN3A1 | O00481 | 10/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15343937 | 0.90 | MEN1 (0.46) | MEN1KMT2ANPSR1BTN3A1CARM1 | |
| SCHEMBL15343939 | 0.90 | MEN1 (0.46) | MEN1KMT2ANPSR1BTN3A1CARM1 | |
| SCHEMBL14934096 | 0.89 | HTT (0.36) | BTN3A1CARM1PRMT6HTTKDM4E | |
| SCHEMBL18476530 | 0.88 | ITGA4 (0.38) | MEN1KMT2ANPSR1BTN3A1LMNA | |
| SCHEMBL14934182 | 0.88 | ITGA4 (0.38) | MEN1KMT2ANPSR1BTN3A1LMNA | |
| SCHEMBL14934170 | 0.88 | ITGA4 (0.38) | MEN1KMT2ANPSR1BTN3A1LMNA | |
| SCHEMBL15343930 | 0.88 | MEN1 (0.55) | MEN1KMT2ANPSR1BTN3A1LMNA | |
| SCHEMBL15343931 | 0.88 | MEN1 (0.55) | MEN1KMT2ANPSR1BTN3A1LMNA | |
| SCHEMBL15203122 | 0.87 | BTN3A1 (0.40) | MEN1KMT2ABTN3A1CARM1PRMT6 | |
| SCHEMBL16015977 | 0.84 | BTN3A1 (0.49) | MEN1KMT2ANPSR1BTN3A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140286903-A1 | Substituted Purine Nucleosides, Phosphoramidate and Phosphordiamidate Derivatives for Treatment if Viral Infections | INHIBITEX, INC. (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140286903-A1 | Substituted Purine Nucleosides, Phosphoramidate and Phosphordiamidate Derivatives for Treatment if Viral Infections | PNP, TYMP, SLC29A1 | MEN1 2615/4885KMT2A 3852/4885NPSR1 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.